Core Viewpoint - The company has initiated the "Thousand Mice, Ten Thousand Antibodies" program to develop antibodies targeting over 1,000 potential drug targets, leveraging its proprietary platforms for antibody development [1] Group 1: Antibody Development Program - The program aims to develop antibodies using the RenMab, RenLite, and RenNano platforms, with a goal of obtaining approximately 1,000,000 fully human antibody sequences by the end of 2024 [1] - The antibody library will include various forms such as monoclonal antibodies, bispecific antibodies, and nanobodies, characterized by high affinity, low immunogenicity, and favorable drug-like properties [1] - The company plans to expand its fully human antibody library to tens of millions in the future [1] Group 2: AI Integration - The company has completed the localization of its AI-driven antibody drug development platform, which is fully integrated with the "Thousand Mice, Ten Thousand Antibodies" program [1] - An "antibody evolution tree" has been established, covering over 1,000 targets and including 1,000,000 fully human antibody sequences, utilizing bioinformatics [1] - The ongoing integration of the AI system with the antibody development program aims to provide global pharmaceutical companies with more efficient research tools and a richer antibody library, enhancing the efficiency of preclinical PCC molecule development [1]
百奥赛图(688796.SH)：已完成AI驱动抗体药物研发平台的本地化部署